Dose-dependent risk of malformations with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry

The Lancet Neurology

Volumn 10, Issue 7, 2011, Pages 609-617

  Tomson, Torbjörn ^a   Battino, Dina ^b   Bonizzoni, Erminio ^c   Craig, John ^d   Lindhout, Dick ^e,f   Sabers, Anne ^g   Perucca, Emilio ^h   Vajda, Frank ⁱ  

^a KAROLINSKA INSTITUTE   (Sweden)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f SEI ilepsy Institute in the Netherlands Foundation   (Netherlands)

^g Rigshospitalet   (Denmark)

^h UNIVERSITY OF PAVIA   (Italy)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; PHENOBARBITAL; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; CHROMOSOME DISORDER; CLEFT LIP FACE PALATE; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; DISEASE REGISTRY; DOSE RESPONSE; EPILEPSY; FEMALE; FETUS OUTCOME; HUMAN; HYPOSPADIAS; KIDNEY MALFORMATION; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE MALFORMATION SYNDROME; NEURAL TUBE DEFECT; POLYDACTYLY; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; SPONTANEOUS ABORTION;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PHENOBARBITAL; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PREVALENCE; PROSPECTIVE STUDIES; REGISTRIES; TRIAZINES; VALPROIC ACID;

EID: 79958781995     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70107-7     Document Type: Article

References (34)

1. Viinikainen K, Heinonen S, Eriksson K, Kalviainen R Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. Epilepsia 2006, 47:186-192.
2. Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008, 81:1-13.
3. Harden CL, Meador KJ, Pennell PB, et al. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review)-II: Teratogenesis and perinatal outcomes. Epilepsia 2009, 50:1237-1246.
4. Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009, 360:1597-1605.
5. Tomson T, Battino D, Craig J, et al. Pregnancy registries: differences, similarities, and possible harmonization. Epilepsia 2010, 51:909-915.
6. Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010, 362:2185-2193.
7. Jentink J, Dolk H, Loane MA, et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ 2010, 341:c6581.
8. Samrén EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997, 38:981-990.
9. Samrén EB, van Duijn CM, Christiaens GC, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999, 46:739-746.
10. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999, 33:145-158.
11. Artama M, Auvinen A, Raudaskoski T, Isojärvi I, Isojärvi J Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005, 64:1874-1878.
12. Vajda FJ, O'Brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and the human teratogenicity: results of the Australian register of antiepileptic drugs in pregnancy. J Clin Neuroscience 2004, 11:854-856.
13. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006, 77:193-198.
14. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006, 66:354-360. EURAP Study Group.
15. Proposal for revised classification of epilepsies and epilepstic syndromes. Epilepsia 1989, 30:389-399. Commission on Classification and Terminology of the International League Against Epilepsy.
16. EUROCAT guide 1.3 and reference documents: instructions for the registration and surveillance of congenital anomalies European Surveillance of Congenital Anomalies, (accessed May 14, 2010). http://www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf.
17. Kenward MG, Carpenter J Multiple imputation: current perspectives. Stat Methods Med Res 2007, 16:199-218.
18. Edwards S, Koch GG, Sollecito WA, Peace KE Summarization, analysis and monitoring of adverse experiences. Statistical issues in drug research and development 1990, 19-170. Marcel Dekker Inc, New York, NY. K. Peace (Ed.).
19. Harden CL, Pennell PB, Koppel BS, et al. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review)-III: vitamin K, folic acid, blood levels, and breast-feeding. Epilepsia 2009, 50:1247-1255.
20. Morrow JI, Hunt SJ, Russell AJ, et al. Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2009, 80:506-511.
21. Jentink J, Bakker MK, Nijenhuis CM, Wilffert B, Jong-van den Berg LT Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid?. Pharmacoepidemiol Drug Saf 2010, 19:803-807.
22. Kaaja E, Kaaja R, Hiilesmaa V Major malformations in offspring of women with epilepsy. Neurology 2003, 60:575-579.
23. Wide K, Winbladh B, Kallen B Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004, 93:174-176.
24. Holmes LB, Wyszynski DF, Lieberman E The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004, 61:673-678.
25. Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005, 64:961-965.
26. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 2009, 50:2130-2139.
27. Hernandez-Diaz S, Smith CR, Wyszynski DF, Holmes LB Risk of major malformations among infants exposed to carbamazepine during pregnancy. Birth Def Res Part A 2007, 79:357.
28. Vinten J, Adab N, Kini U, Gorry J, Gregg J, Baker GA Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005, 64:949-954.
29. Cunnington M, Ferber S, Quarteny G Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. Epilepsia 2007, 48:1207-1210.
30. Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008, 70:2152-2158.
31. Meador KJ, Baker GA, Browning N, et al. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 2011, 134:396-404.
32. Utilization of antiepileptic drugs during pregnancy: comparative patterns in 38 countries based on data from the EURAP registry. Epilepsia 2009, 50:2305-2309. EURAP Study Group.
33. Adab N, Kini U, Vinten J, Ayres J, et al. The longer term outcome of children born to mothers with epilepsy. Neurol Neurosurg Psychiatry 2004, 75:1575-1583.
34. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1016-1026.